Medications developed for other uses show potential to curb cervical cancer

December 16, 2013 by Rob Forman, Rutgers University
Medications developed for other uses show potential to curb cervical cancer

Two existing drugs – one the active ingredient in an anti-fungal medication and the other now used to control iron levels in the blood – both show promise as potential treatments for cervical cancer, according to newly published research by scientists at Rutgers New Jersey Medical School.

Cervical cancer is the third most common gynecologic cancer in the United States, and takes the life of one of every three women diagnosed with it.

"Cervical cancer still takes a terrible toll, despite advances in prevention, detection and treatment," says Michael Mathews, the senior member of the research team. Their article, whose first author is Elisabeth Mémin, has been published online by the journal Cancer Research.

"Early stage disease is curable," adds co-author Bernadette Cracchiolo, director of gynecologic oncology at the school, "but late stage and recurrent disease have limited treatment options. We need novel concepts, novel agents that can save lives in those cases, especially for African-American women, whose death rate is twice that of Caucasians. We believe our new research offers those."

The research demonstrates how the two drugs, ciclopirox (anti-fungal) and deferiprone (blood treatment), effectively inhibit an enzyme called deoxyhypusine hydroxylase (DOHH). The enzyme is believed to be essential to the molecular chain of events that leads to cervical cancer.

The researchers performed lab experiments on derived from a cervical cancer and found that when DOHH is blocked, a protein known as eIF5A fails to mature. That, in turn, alters the expression of genes that without the medications would cause to proliferate. "Some gene products go down and others go up, because mature eIF5A has more than one biochemical action inside cells," Mathews explains. "For cell proliferation, each drug's dual action is like both easing off the accelerator and depressing the brake pedal."

For Mathews and his Rutgers colleague Hartmut Hanauske-Abel, this is the second significant success announced within a matter of weeks involving these two medications. In September, a research team they led published similarly exciting findings in the journal PLOS ONE about HIV – evidence that the same two drugs eradicated the virus from infected cells examined in lab cultures.

The drugs had two separate effects on HIV. First, both medications prevented the virus from reproducing within cells. Second, by disturbing the function of the mitochondria, the cells' power stations, the drugs caused HIV-infected cells to self-destruct while sparing healthy cells. Once the medications were discontinued, HIV infection did not return. If these promising results are corroborated in clinical trials, they would represent a major advance over current treatments, which patients must take as long as they live. Existing antiretroviral drugs don't eliminate HIV but only inhibit its multiplication. If current cocktails of drugs are discontinued, the disease returns.

So what made Mathews and Hanauske-Abel decide that ciclopirox and deferiprone could act against both HIV and cervical cancer? The key is contained in the two drugs' molecular structures, according to Mathews.

"While ciclopirox and deferiprone were developed for unrelated uses, Hartmut's knowledge of enzymes and pharmacology suggested that both drugs could influence some of the most basic processes that occur within human cells," he says. "We then designed experiments that could help us take advantage of those properties, and our predictions were validated."

An essential aspect of the research team's work with these medications is that both are approved by the Food and Drug Administration for their originally intended uses, which means they are considered safe for use by human patients. Repurposing the medications to treat and HIV creates a potentially huge shortcut to approval if the drugs prove their worth.

"A drug produced from scratch needs to be proven both safe and effective before the FDA will permit its use, and that is a painstaking and expensive process requiring extensive animal experiments," Hanauske-Abel says. "If we start with an existing , FDA-approved for an 'old' indication, its safety is already established and the innovation process becomes much shorter."

Explore further: Nail fungus drug might help against HIV, study suggests

More information: Hanauske-Abel HM, Saxena D, Palumbo PE, Hanauske A-R, Luchessi AD, et al. (2013) Drug-Induced Reactivation of Apoptosis Abrogates HIV-1 Infection. PLoS ONE 8(9): e74414. DOI: 10.1371/journal.pone.0074414

Related Stories

Nail fungus drug might help against HIV, study suggests

September 24, 2013
(HealthDay)—A common drug used to treat nail fungus may hold promise against HIV, the virus that causes AIDS, according to a new study.

Discovery paves way for personalized cancer treatment

November 18, 2013
A prostate cancer researcher at the University of Alberta and his team have discovered how to improve currently available cancer drugs so the medication could be personalized for individual patients.

Drug delivery system successfully treats deadly ovarian cancer in mice

December 6, 2013
(Medical Xpress)—Scientists at Rutgers University have developed a targeted drug delivery system that they believe could make ovarian cancer more treatable and increase survival rates for the most deadly gynecological cancer ...

Research makes connetion between tubal ligation and increase in cervical cancer rates

January 14, 2013
the surgical tying or severing of fallopian tubes to prohibit pregnancy – have less frequent Pap smears, which puts them at an increased risk for cervical cancer, according to research recently released by a team that included ...

Some types of papilloma virus might prevent cervical cancer

April 10, 2013
(Medical Xpress)—Certain types of papilloma virus might actually prevent cervical cancer, according to a new study by researchers from The University of Manchester.

HIV drug could prevent cervical cancer

May 3, 2011
A widely used HIV drug could be used to prevent cervical cancer caused by infection with the human papilloma virus (HPV), say scientists.

Recommended for you

New approach attacks 'undruggable' cancers from the outside in

January 23, 2018
Cancer researchers have made great strides in developing targeted therapies that treat the specific genetic mutations underlying a patient's cancer. However, many of the most common cancer-causing genes are so central to ...

Study: Cells of three advanced cancers die with drug-like compounds that reverse chemo failure

January 23, 2018
Researchers at Southern Methodist University have discovered three drug-like compounds that successfully reverse chemotherapy failure in three of the most commonly aggressive cancers—ovarian, prostate and breast.

'Hijacker' drives cancer in some patients with high-risk neuroblastoma

January 23, 2018
Researchers have identified mechanisms that drive about 10 percent of high-risk neuroblastoma cases and have used a new approach to show how the cancer genome "hijacks" DNA that regulates other genes. The resulting insights ...

Enzyme inhibitor combined with chemotherapy delays glioblastoma growth

January 23, 2018
In animal experiments, a human-derived glioblastoma significantly regressed when treated with the combination of an experimental enzyme inhibitor and the standard glioblastoma chemotherapy drug, temozolomide.

Researchers identify a protein that keeps metastatic breast cancer cells dormant

January 23, 2018
A study headed by ICREA researcher Roger Gomis at the Institute for Research in Biomedicine (IRB Barcelona) has identified the genes involved in the latent asymptomatic state of breast cancer metastases. The work sheds light ...

Boosting cancer therapy with cross-dressed immune cells

January 22, 2018
Researchers at EPFL have created artificial molecules that can help the immune system to recognize and attack cancer tumors. The study is published in Nature Methods.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.